Back to search results

Allergy Delabeling for Beta-Lactam Allergies in Patients with Blood Cancers

This study is looking at how a special program called RENEW-IN can help patients with blood cancers (hematologic malignancy) who have a reported allergy to beta-lactam antibiotics (like penicillin or cephalosporins). Many people are told they have these allergies, but often they don't. The RENEW-IN program will carefully check your allergy history to see if you can safely take these important antibiotics. The goal is to see if this program can help patients use antibiotics more effectively and improve their hospital stays. This study plans to include about 3800 participants. The current status of the study is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It aims to enroll about 3800 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from when they join the study until they leave the hospital or pass away, for up to 36 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07133074

Allergy Delabeling in Antibiotic Stewardship - Intervention

Recruiting
PHASE4Ages 18+Interventional
Abramson Cancer Center at Penn Medicine
~3,800 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:RENEW-IN Algorithm for assessment of a beta-lactam interventionEMR Review

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Antibiotic Days of therapy
Measured over From baseline enrollment to end of index hospitalization or death, up to 36 months
+1 more outcome measured

Conditions

Beta Lactam Allergy
Hematologic Malignancy

Explore related trials

Malignant neoplasm of lymphoid, hematopoietic and/or related tissue

NCT07133074

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvaniano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Ebbing Lautenbach, MD,MPH,MSCE
[email protected]
215-898-6977
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service
reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and/or carbapenem)

Exclusion

patients with a history of severe cutaneous adverse reaction
patients with a history of Stevens-Johnson syndrome
patients with a history of toxic epidermal necrolysis
patients with a history of drug-induced exfoliative dermatitis
patients with a history of drug reaction with eosinophilia and systemic symptoms
patients with a history of acute generalized exanthematous pustulosis

What this trial measures

  • Antibiotic Days of therapyFrom baseline enrollment to end of index hospitalization or death, up to 36 months

    Proportion of participants prescribed an antibiotic during index hospitalization, from enrollment in the study to hospital discharge or death, whichever occurs first

  • Hospital length of stayFrom baseline enrollment to end of index index hospitalization or death, up to 36 months

    Number of days participants are admitted to the hospital during the index visit, from enrollment in the study to hospital discharge or death, whichever occurs first